You are here: Industry Insights > Santhera

News List

Santhera to Obtain Worldwide Rights to Vamorolone americanpharmaceuticalreview
September 07, 2020
Santhera Pharmaceuticals has signed agreements with Idorsia and ReveraGen BioPharma, making Santhera a direct license holder of vamorolone.
Santhera obtains exclusive licence to DMD drug vamorolone pharmaceutical-technology
September 04, 2020
Santhera Pharmaceuticals has entered agreements with Idorsia and ReveraGen BioPharma to gain exclusive global rights to Duchenne muscular dystrophy (DMD) drug, called vamorolone.
MHRA extends access to Santhera's DMD drug via the EAMS pharmatimes
June 24, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed for a further year the Early Access to Medicines Scheme (EAMS) scientific opinion for Santhera's Duchenne muscular dystrophy (DMD) drug idebenone.
Santhera, CSHL to Investigate Lonodelestat in COVID-19-related ARDS contractpharma
April 28, 2020
Lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), has potential as a therapeutic intervention for COVID-19-related ARDS.
Santhera licenses Leber’s hereditary optic neuropathy drug to Chiesi pharmaceutical-technology
August 06, 2019
Santhera Pharmaceuticals has licensed a drug called Raxone, indicated for the treatment of Leber’s hereditary optic neuropathy (LHON), to Chiesi Farmaceutici (Chiesi Group).
Santhera, Chiesi Group Enter Raxone License Agreement contractpharma
May 29, 2019
Chiesi gains rights to Raxone in LHON and all other ophthalmological indications in deal valued at €186 million.
Santhera’s cystic fibrosis drug POL6014 in line for orphan status pharmatimes
October 19, 2018
Santhera says its experimental cystic fibrosis drug POL6014 is likely to be designated an orphan drug in the next 30 days, putting the firm in line to receive...
Santhera’s Raxone fails in MS trial pharmatimes
March 07, 2018
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.
Santhera's Raxone rejected in Europe for Duchenne muscular dystrophy pharmafile
January 30, 2018
While the EMA’s Committee for Medicinal products for Human Use recommended a spree of treatments over the past week, Santhera’s Raxone was left out, rejected by the advisory panel and given a negative opinion in the treatment of Duchenne muscular dystrop